An SPC cannot be granted for a medicinal product which is protected in the basic patent and already on the market – even if a new formulation of an “old” active substance of this medicinal product represents and the effect is thus improved, the ECJ ruled in the case Abraxis. Already in December 2018 the … Continue reading New formulation of an active ingredient: no SPC